DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease

Information source: Astellas Pharma Inc
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Metastatic Prostate Cancer

Intervention: Eligard (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Astellas Pharma Europe Ltd.

Official(s) and/or principal investigator(s):
Clinical Study Manager, Study Chair, Affiliation: Astellas Pharma Europe Ltd.

Overall contact:
Medical Affairs Europe, Phone: +44(0)20 3379 8000, Email: Astellas.registration@astellas.com

Summary

The purpose of this study is to investigate the effect of the study medication (Eligard) on cancer markers (in the blood) of prostate cancer.

Clinical Details

Official title: An Exploratory, Open Label, Single-arm Study to Evaluate the Effect of Eligard 6-month on Biomarkers of Disease in Patients With Metastatic Prostate Cancer

Study design: Intervention Model: Single Group Assignment, Masking: Open Label

Primary outcome:

Changes from baseline of Testosterone levels in serum

Changes from baseline of PSA level in serum

Changes from baseline of PCA3 score in urine

Changes from baseline of Number of PSA mRNA copies in blood/PBMC

Changes from baseline of Number of PCA3 mRNA copies in blood/PBMC

Changes from baseline of Number of TMPRSS2-ERG mRNA copies in blood/PBMC

Secondary outcome: Number of Adverse Events from screening to the end of study visit (as reported by the investigator based on Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.3)

Detailed description: The main objective of the study is to explore the effect of Eligard on the following prostate cancer biomarkers: Testosterone in serum, Prostate Specific Antigen (PSA) in serum, Prostate Cancer Antigen (PCA3 score) in urine, PSA mRNA in blood/Peripheral Blood Mononuclear Cell (PBMC), PCA3 mRNA in blood/PBMC, Transmembrane protease, serine 2-Ets Related Gene (TMPRSS2-ERG) mRNA in blood/PBMC A blood sample for RNA analysis will also be collected and stored for future investigation in patients giving specific informed consent.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Confirmed metastatic prostate cancer for whom androgen deprivation therapy (ADT) is

indicated.

- Non-castrate level of testosterone (≥ 8 nmol/L (230 ng/dL)) at screening.

- Serum PSA ≥ 5 ng/mL at screening.

- Eastern Cooperative Oncology Group (ECOG) score of 0-2

- A life expectancy of at least 12 months.

- Is able to tolerate injection of study drug and comply with the study requirements.

- Positive blood PSA mRNA at screening. A positive PSA mRNA in PBMCs (defined as

exceeding the Limit of Detection [LoD] for the central lab assay, i. e. ≥ 10 copies per Polymerase Chain Reaction, PCR). Exclusion Criteria:

- History of bilateral orchidectomy.

- History of any hormonal treatment/therapy with GnRH agonist, GnRH anti-agonist within

6 months of enrolment.

- Treatment with anti-androgens (except where used to prevent testosterone flare up,

starting up to 2 weeks prior to Eligard injection, according to local treatment guidelines), 5-α reductase inhibitors, estrogens and/or other any investigational hormone-derivative within 3 months of enrolment or 5-times the half-life, whichever is longer.

- Any previous treatment with chemotherapy treatment for prostate cancer prior to the

screening visit or within 6 months prior to screening for any other cancer.

- Patients previously treated for cancer with hormonal therapy in whom treatment was

stopped due to lack of efficacy, progression of the disease or lack of tolerability.

- Previous treatments for cancer (including prostate cancer) within 6 months prior to

enrolment: immunotherapy, external beam radiotherapy, brachytherapy, thermotherapy, or biological response modifiers (e. g. cytokines).

- Known or suspected spinal cord compression or evidence of spinal metastases with risk

of spinal compression.

- Uni- or bilateral ureteric obstruction.

- Requiring concomitant use of anti-androgens during the course of the study (except

where used to prevent testosterone flare up, starting up to 2 weeks prior to Eligard injection and continuing for up to 3 weeks, according to local treatment guidelines).

- Previous or concomitant malignancies at other sites except effectively treated

non-melanoma skin cancer or an effectively treated malignancy that has been in remission for at least 5 years.

- Major surgery within 2 months prior to enrolment.

- Total bilirubin > 1. 5 times the upper limit of normal (ULN) at screening. This will

not apply to subjects with Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of evidence of hemolysis or hepatic pathology), who will be allowed in consultation with the sponsor.

- Participation in any clinical study within ≤ 1 month prior to screening (or 5 half

lives of the drugs under investigation, whichever is greater).

- Not available for follow-up assessments or unable to comply with study requirements.

- Known or suspected hypersensitivity to leuprorelin acetate, to other GnRH agonists or

to any of the excipients of Eligard.

- Male subjects who are intending to donate sperm within 9 months following the

injection of Eligard

- Male subjects and their female spouses/partners who are of childbearing potential and

are NOT using highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at Screening and continuing for 9 months from the time of the Eligard injection. Acceptable forms include:

- Established use of oral, injected or implanted hormonal methods of

contraception.

- Placement of an intrauterine device (IUD) or intrauterine system (IUS).

- Barrier methods of contraception: Condom OR Occlusive cap (diaphragm or

cervical/vault caps) with spermicidal foam/gel/film/cream/suppository

- Absolute neutrophil count < 1,500/μL, platelet count < 100,000/μL, and hemoglobin <

5. 6 mmol/L (9 g/dL) at screening.

- Alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) > 2 times ULN at

screening.

- Creatinine > 177 μmol/L (2 mg/dL) at screening.

- Albumin ≤ 30 g/L (3. 0 g/dL) at screening.

Locations and Contacts

Medical Affairs Europe, Phone: +44(0)20 3379 8000, Email: Astellas.registration@astellas.com

Site: 31003, 's-Hertogenbosch 5200 ME, Netherlands; Active, not recruiting

Site: 31002, Hengelo 7555 DL, Netherlands; Active, not recruiting

Site: 31005, Nieuwegein 3435 CM, Netherlands; Active, not recruiting

Site: 31001, Nijmegen 6532 SZ, Netherlands; Recruiting

Site: 31004, Nijmegen 6525 GA, Netherlands; Active, not recruiting

Additional Information

Starting date: August 2014
Last updated: June 1, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017